Ulcerative Colitis Maintenance Therapy with Vedolizumab

Evidence Supporting Medical Necessity

The British Society of Gastroenterology recommends vedolizumab for induction and maintenance of remission in patients with moderate to severe ulcerative colitis with moderate certainty evidence 1, 4
The Toronto Consensus Guidelines strongly recommend continued vedolizumab therapy to maintain complete corticosteroid-free remission in patients who respond to induction therapy (Strong recommendation, moderate-quality evidence) 2, 3, 5
Maintenance therapy with vedolizumab has shown significantly higher rates of complete remission compared with placebo (44.8% vs 15.9%, p<0.001) in clinical trials 2

The patient has demonstrated clinical response to therapy as evidenced by documentation noting "no diarrhea or blood in stool" and "no flares since starting" therapy, which is consistent with the American Gastroenterological Association's recommendations for ulcerative colitis management 2, 3
The patient has documented endoscopic remission with "normal mucosa" on colonoscopy, indicating mucosal healing, as recommended by the European Crohn’s and Colitis Organisation 1, 4

Vedolizumab has demonstrated a favorable long-term safety profile with no new safety signals observed during extended treatment periods, according to the National Institute for Health and Care Excellence 2
The proportion of patients experiencing adverse events is similar between vedolizumab and placebo groups (84% vs 87%), as is the rate of serious adverse events (12% vs 14%), as reported by the American College of Gastroenterology 2

The patient's clinical notes indicate stable disease with 1-2 soft bowel movements per day, no diarrhea, and no blood in stool, which is consistent with the clinical response criteria established by the Crohn’s & Colitis Foundation 2, 3
Colonoscopy from 3/28/23 showed normal mucosa, confirming endoscopic remission, as recommended by the British Society of Gastroenterology 1, 4